Eupraxia Pharmaceuticals Inc
TSX:EPRX
Eupraxia Pharmaceuticals Inc
TSX:EPRX
Price:
4 CAD
1.01%
Market Closed
Updated:
May 21, 2024
P/E
Price to Earnings
Price to Earnings
-2.7
Current
-3.7
Median
26.1
Industry
Higher
than median
Lower
than industry value
Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.
P/E
=-2.7
Market Cap
/
142.5m
Net Income
-53.4m
All Countries
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| CA |
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
142.5m CAD | -2.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
290.6B USD | 48.8 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
168.7B USD | 44.8 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
115.2B USD | 28.7 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
108.8B USD | 28.2 | |
| AU |
|
CSL Ltd
ASX:CSL
|
134.1B AUD | 36.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
84.6B USD | 174.8 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
54B USD | -9 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | -57.5 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
33.7B USD | 28.9 | |
| KR |
|
Celltrion Inc
KRX:068270
|
38.7T KRW | 72.3 |
P/E Forward Multiples
Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/E
-3.5
2-Years Forward
P/E
-3.1
3-Years Forward
P/E
-7.4
You don't have any saved screeners yet
